Literature DB >> 23382334

Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels.

Cristiana Catena1, GianLuca Colussi, Marica Valeri, Leonardo A Sechi.   

Abstract

BACKGROUND: Plasma aldosterone concentration is an independent determinant of left ventricular (LV) mass in hypertensive patients, and is related to some hemostatic variables along with it may contribute to a prothrombotic state. We conducted a study to investigate the relationship between hemostatic variables, plasma aldosterone, and cardiac morphology and function in essential hypertension.
METHODS: In 205 patients with untreated essential hypertension, we measured components of the renin-angiotensin-aldosterone system, plasma levels of fibrinogen, D-dimer, prothrombin fragment 1 + 2 (F1 + 2), and plasminogen activator inhibitor-1 (PAI-1), and assessed cardiac characteristics with standard echocardiography. For statistical purpose, patients were divided into two groups according to whether their median value of plasma aldosterone was > 125 pg/ml or < 125 pg/ml.
RESULTS: Left ventricular mass index (LVMI) was significantly greater in patients with a high (> 51 ± 13 g/m(2.7)) than with a low plasma aldosterone level (< 41 ± 11 g/m(2.7); P < 0.01) only in patients with fibrinogen levels in the highest tertile. Significant interaction was observed between plasma fibrinogen and aldosterone in the association with LVMI (P = 0.04). Left ventricular mass index was significantly and directly related to age, systolic blood pressure (BP), body mass index (BMI), plasma aldosterone, fibrinogen, and D-dimer levels, whereas no relationships were observed between echocardiographic parameters and other hemostatic variables. Fibrinogen was directly related to age, systolic BP, plasma aldosterone, LVMI, relative wall thickness, and left atrial diameter. Multivariate analysis indicated that LVMI was related to plasma fibrinogen and aldosterone (both P < 0.01) independently of age, BP, and BMI.
CONCLUSIONS: Plasma fibrinogen levels interact with plasma aldosterone in its association with left ventricular mass in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23382334     DOI: 10.1093/ajh/hps006

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Aldosterone and abnormal left ventricular geometry in chronic kidney disease.

Authors:  Cesare Cuspidi; Marijana Tadic; Carla Sala
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 2.  Clinical and prognostic value of hypertensive cardiac damage in the PAMELA Study.

Authors:  Cesare Cuspidi; Carla Sala; Anna Casati; Michele Bombelli; Guido Grassi; Giuseppe Mancia
Journal:  Hypertens Res       Date:  2016-11-17       Impact factor: 3.872

Review 3.  Targeting subclinical organ damage in obstructive sleep apnea: a narrative review.

Authors:  Cesare Cuspidi; Marijana Tadic; Elisa Gherbesi; Carla Sala; Guido Grassi
Journal:  J Hum Hypertens       Date:  2020-08-14       Impact factor: 3.012

4.  Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism.

Authors:  Chien-Ting Pan; Xue-Ming Wu; Cheng-Hsuan Tsai; Yi-Yao Chang; Zheng-Wei Chen; Chin-Chen Chang; Bo-Ching Lee; Che-Wei Liao; Ya-Li Chen; Lung-Chun Lin; Yi-Ru Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-19       Impact factor: 5.555

5.  Relationship between Plasma Aldosterone Levels and Left Ventricular Mass in Hypertensive Africans.

Authors:  Adewole Adebiyi; Olubayo Akinosun; Chibuike Nwafor; Ayodele Falase
Journal:  Int J Hypertens       Date:  2013-10-07       Impact factor: 2.420

Review 6.  Salt, Aldosterone, and Parathyroid Hormone: What Is the Relevance for Organ Damage?

Authors:  Cristiana Catena; Gian Luca Colussi; Gabriele Brosolo; Nicole Bertin; Marileda Novello; Andrea Palomba; Leonardo A Sechi
Journal:  Int J Endocrinol       Date:  2017-09-19       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.